1KA logo

GH Research PLCDB:1KA Stock Report

Market Cap €1.1b
Share Price
€15.70
€30.43
48.4% undervalued intrinsic discount
1Y96.3%
7D6.8%
Portfolio Value
​
View

GH Research PLC

DB:1KA Stock Report

Market Cap: €1.1b

GH Research (1KA) Stock Overview

Together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. More details

1KA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the German market


1KA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 74.1% undervalued intrinsic discount
5022.2%Revenue growth p.a.
3.5k
22
2
49
23d ago

GH Research PLC Competitors

Price History & Performance

Summary of share price highs, lows and changes for GH Research
Historical stock prices
Current Share PriceUS$15.70
52 Week HighUS$20.20
52 Week LowUS$7.50
Beta1
1 Month Change33.05%
3 Month Change14.60%
1 Year Change96.25%
3 Year Change115.07%
5 Year Changen/a
Change since IPO8.31%

Recent News & Updates

Recent updates

Shareholder Returns

1KADE PharmaceuticalsDE Market
7D6.8%-5.7%-2.8%
1Y96.3%14.9%3.7%

Return vs Industry: 1KA exceeded the German Pharmaceuticals industry which returned 14.9% over the past year.

Return vs Market: 1KA exceeded the German Market which returned 3.7% over the past year.

Price Volatility

Is 1KA's price volatile compared to industry and market?
1KA volatility
1KA Average Weekly Movement13.7%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement6.0%
10% most volatile stocks in DE Market13.7%
10% least volatile stocks in DE Market2.6%

Stable Share Price: 1KA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 1KA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201873Villy Valchevawww.ghres.com

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.

GH Research PLC Fundamentals Summary

How do GH Research's earnings and revenue compare to its market cap?
1KA fundamental statistics
Market cap€1.07b
Earnings (TTM)-€41.18m
Revenue (TTM)n/a
0.0x
P/S Ratio
-26.0x
P/E Ratio

Is 1KA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1KA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$48.26m
Earnings-US$48.26m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.78
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 1KA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/26 07:12
End of Day Share Price 2026/04/24 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GH Research PLC is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sumant Satchidanand KulkarniCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.
Joshua SchimmerCantor Fitzgerald & Co.